Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 6, 2026BJUI CompassOpen Access

Cost‐effectiveness analysis of a biopsy‐free diagnostic strategy for prostate cancer using mpMRI and PSMA‐PET/CT

View Full Paper
Ask AI
Bookmark
Share

Authors

JTJoshua Yi Min TungRLRachel Shu‐En LauETE H C Teo

Discussion

Loading...

Member takes

Overview

Cost-effectiveness analysis evaluates a biopsy-free diagnostic strategy for prostate cancer in men with raised PSA, indicating its benefits over conventional methods.

Key Points

  • This analysis aims to assess the economic viability of combining PSMA PET/CT and mpMRI for diagnosing clinically significant prostate cancer without biopsies.
  • Developed a decision tree model comparing a biopsy-free approach with a conventional mpMRI and biopsy strategy.
  • Evaluated costs and Quality-Adjusted-Life-Years (QALYs) associated with each strategy.
  • Conducted one-way and probabilistic sensitivity analyses to measure robustness of findings.
  • The combined imaging strategy improved effectiveness by 0.04 QALY but was SGD$4088.03 more expensive than the conventional strategy.
  • The incremental cost-effectiveness ratio (ICER) was SGD$92782.87 per QALY.
  • Missed diagnoses were lower in the combined strategy (3.5%) compared to the conventional strategy (13.9%).
  • The combined approach was deemed cost-effective at willingness-to-pay thresholds of SGD$121160 and SGD$363480.

Cite This Study

Tung et al. (2026) studied this question.

synapsesocial.com/papers/6985852f8f7c464f2300860bhttps://doi.org/10.1002/bco2.70172
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer2019 · 655 citations
  2. 2Modernizing the Diagnostic and Decision-Making Pathway for Prostate Cancer2014 · 21 citations
  3. 3An Analysis of Waiting Times for the Diagnosis and Treatment of Patients with Prostate Cancer Established by the Requirements of the Fast-Track Cancer Treatment Pathway, Taking into Account Treatment Steps2025 · 2 citations
  4. 4Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial2023 · 51 citations
  5. 5A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancer2025 · 15 citations